A Multi-center, Phase I, Open Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Efficacy of TWP-102 in Patients With Advanced Malignancies
Latest Information Update: 07 Aug 2023
At a glance
- Drugs TWP-102 (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors Shandong TheraWisdom Biopharm
- 07 Mar 2022 Status changed from not yet recruiting to recruiting.
- 02 Sep 2021 New trial record